Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

PHASE2CompletedINTERVENTIONAL

Enrollment

257

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

March 6, 2023

Study Completion Date

March 6, 2023

Conditions

Dry Eye

Interventions

DRUG

0.3% YP-P10 Ophthalmic Solution

Drug: YP-P10 Ophthalmic Solution

DRUG

1% YP-P10 Ophthalmic Solution

Drug: YP-P10 Ophthalmic Solution

DRUG

YP-P10 Placebo Ophthalmic Solution (vehicle)

Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)

Trial Locations (7)

NC Eye Associates, Apex

Oculus Research, Garner

Total Eye Care, Memphis

Vision Institute, Colorado Springs

Cornea Consultants of Arizona, Phoenix

Aesthetic Eye Care Institute, Newport Beach

Andover Eye Associates, Andover

All Listed Sponsors

lead

Yuyu Pharma, Inc.

INDUSTRY